Lilly/Alkermes Inhaled Insulin To Enter Late-Stage Development
This article was originally published in The Pink Sheet Daily
Executive Summary
The companies are finalizing plans for Phase II and Phase III trials following successful Phase II study in type 1 diabetes and completion of manufacturing scale-up and inhaler device development. The partnership is Lilly’s third stab at non-injectable insulin development.
You may also be interested in...
Lilly Drops Inhaled-Insulin Program With Alkermes
Third casualty in the space leaves one late-stage player standing.
Lilly Drops Inhaled-Insulin Program With Alkermes
Third casualty in the space leaves one late-stage player standing.
Nastech/Amylin’s Exenatide Nasal Spray Deal Could Be Shot In The Arm For Lilly
Lilly, which markets injectable exenatide, may inherit commercialization rights to the nasal spray formulation if Nastech/Amylin’s development proves successful.